PolyPeptide Group is forecast to grow earnings and revenue by 44.4% and 14.2% per annum respectively. EPS is expected to grow by 44.4% per annum. Return on equity is forecast to be 15.2% in 3 years.
Key information
44.4%
Earnings growth rate
44.36%
EPS growth rate
Life Sciences earnings growth
56.6%
Revenue growth rate
14.2%
Future return on equity
15.20%
Analyst coverage
Low
Last updated
25 Jun 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
LSE:0AAJ - Analysts future estimates and past financials data (EUR Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
662
76
-12
94
3
12/31/2027
568
44
-35
63
3
12/31/2026
492
24
-45
40
3
12/31/2025
389
-21
-31
78
N/A
9/30/2025
379
-28
0
108
N/A
6/30/2025
369
-35
32
139
N/A
3/31/2025
353
-27
17
114
N/A
12/31/2024
337
-20
2
89
N/A
9/30/2024
330
-24
16
87
N/A
6/30/2024
324
-29
30
85
N/A
3/31/2024
322
-40
5
61
N/A
12/31/2023
320
-51
-20
36
N/A
9/30/2023
300
-44
-62
1
N/A
6/30/2023
279
-37
-104
-35
N/A
3/31/2023
280
-14
-89
-15
N/A
12/31/2022
281
8
-73
5
N/A
9/30/2022
281
20
-74
7
N/A
6/30/2022
281
33
-75
9
N/A
3/31/2022
281
40
-48
33
N/A
12/31/2021
282
47
-20
57
N/A
9/30/2021
277
48
-4
67
N/A
6/30/2021
271
48
13
77
N/A
3/31/2021
248
40
10
63
N/A
12/31/2020
224
31
6
49
N/A
12/31/2019
203
26
36
56
N/A
12/31/2018
181
24
N/A
23
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0AAJ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.4%).
Earnings vs Market: 0AAJ is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0AAJ is expected to become profitable in the next 3 years.
Revenue vs Market: 0AAJ's revenue (14.2% per year) is forecast to grow faster than the UK market (4.7% per year).
High Growth Revenue: 0AAJ's revenue (14.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0AAJ's Return on Equity is forecast to be low in 3 years time (15.2%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/06 09:29
End of Day Share Price
2026/07/06 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PolyPeptide Group AG is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.